BAT5906 / Bio-Thera Solutions - LARVOL DELTA

Efficacy Evaluation Study of BAT5906 and Lucentis® in Patients With Macular Degeneration (clinicaltrials.gov) - P3 | N=488 | Completed | Sponsor: Bio-Thera Solutions | Active, not recruiting ➔ Completed | Trial primary completion date: Apr 2024 ➔ Apr 2025

Trial completion • Trial primary completion date • Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration

A Muticenter. Randomized, Double-blind Phase l linical Study Comparina the Eficacy and Safety of BAT5906 and Ranibizumab (ucentise in Patients With Neovascular Age-related Macular Degeneration (ChiCTR) - P3 | N=488 | Completed | Sponsor: Eye Hospital, Wenzhou Medical University; Eye Hospital, Wenzhou Medical University

New P3 trial • Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration

Efficacy Evaluation Study of BAT5906 and Lucentis® in Patients With Macular Degeneration (clinicaltrials.gov) - P3 | N=488 | Active, not recruiting | Sponsor: Bio-Thera Solutions | Recruiting ➔ Active, not recruiting

Enrollment closed • Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration

Clinical Study of the Safety and Efficacy of BAT5906 Injection (clinicaltrials.gov) - P1/2 | N=60 | Completed | Sponsor: Bio-Thera Solutions | Recruiting ➔ Completed | Trial completion date: Dec 2022 ➔ Nov 2023 | Trial primary completion date: Dec 2022 ➔ Nov 2023

Trial completion • Trial completion date • Trial primary completion date • Diabetic Macular Edema • Ophthalmology • VEGFA

Efficacy Evaluation Study of BAT5906 and Lucentis® in Patients With Macular Degeneration (clinicaltrials.gov) - P3 | N=488 | Recruiting | Sponsor: Bio-Thera Solutions | Not yet recruiting ➔ Recruiting

Enrollment open • Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration

Efficacy Evaluation Study of BAT5906 and Lucentis® in Patients With Macular Degeneration (clinicaltrials.gov) - P3 | N=488 | Not yet recruiting | Sponsor: Bio-Thera Solutions

New P3 trial • Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration

A Phase I Clinical Trial of BAT5906 Injection in Patients With Wet Age-related Macular Degeneration (clinicaltrials.gov) - P1; N=24; Completed; Sponsor: Bio-Thera Solutions; Recruiting ➔ Completed; N=39 ➔ 24; Trial completion date: Jun 2020 ➔ Apr 2021; Trial primary completion date: Jun 2020 ➔ Feb 2021

Enrollment change • Trial completion • Trial completion date • Trial primary completion date • Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration

Newly added product (clinicaltrials.gov) - P1, AMD, Ophthalmology

Pipeline update